CombiCTx: screening diffusion gradients of anti-cancer drug combinations
Open Access
- 1 January 2026
- journal article
- research article
- Published by Royal Society of Chemistry (RSC) in Lab on a Chip
- Vol. 26 (3) , 695-710
Abstract
In the CombiCTx assay, drugs diffuse from reservoirs into a surrounding gel and expose tumor cells to overlapping dynamic drug gradients, and cell responses can be monitored by time-lapse microscopy.Keywords
All Related Versions
Funding Information
- VINNOVA (2019-00029)
- Cancerfonden (20 1285 PjF)
- Cancerfonden (23 2692 Pj 01 H)
- Cancerfonden (23 2776 P)
- Cancerfonden (CAN 24 3519 Pj 01 H)
- Göran Gustafssons Stiftelser
- Svenska Sällskapet för Medicinsk Forskning (S17-0092)
- Vetenskapsrådet (2020-02367)
- Vetenskapsrådet (2024-03166)
- Vetenskapsrådet (2021-01628)
This publication has 61 references indexed in Scilit:
- A comprehensive review on doxorubicin: mechanisms, toxicity, clinical trials, combination therapies and nanoformulations in breast cancerDrug Delivery and Translational Research, 2024
- Quantitative imaging of doxorubicin diffusion and cellular uptake in biomimetic gels with human liver tumor cellsDrug Delivery and Translational Research, 2023
- Neoadjuvant therapy with doxorubicin-cyclophosphamide followed by weekly paclitaxel in early breast cancer: a retrospective analysis of 200 consecutive patients treated in a single center with a median follow-up of 9.5 yearsBreast Cancer Research and Treatment, 2022
- Could 3D models of cancer enhance drug screening?Biomaterials, 2020
- Fibrosis in tissue engineering and regenerative medicine: treat or trigger?Advanced Drug Delivery Reviews, 2019
- Analysis of drug combinations: current methodological landscapePharmacology Research & Perspectives, 2015
- A phase I clinical trial of navitoclax, a targeted high-affinity Bcl-2 family inhibitor, in combination with gemcitabine in patients with solid tumorsInvestigational New Drugs, 2014
- Fluorescent Probes2013
- The Discovery of Navitoclax, a Bcl-2 Family Inhibitor2012
- Induction of a Common Pathway of Apoptosis by StaurosporineExperimental Cell Research, 1994